Portage Biotech
Yahoo Finance • 4 months ago
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.59%
Investing.com – U.S. stocks were mixed after the close on Thursday, as gains in the Oil&Gas, Industrials and Basic Materials sectors led shares higher while losses in the Technology, Telecoms and Consumer Services sectors led shares lower.... Full story
Yahoo Finance • 4 months ago
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.14%
Investing.com – U.S. stocks were higher after the close on Friday, as gains in the Consumer Goods, Oil&Gas and Technology sectors led shares higher. At the close in NYSE, the Dow Jones Industrial Average added 1.14% to hit a new 1-month h... Full story
Yahoo Finance • last year
11 Most Volatile Stocks Under $5 For Day Trading
In this piece, we will take a look at the 11 most volatile stocks under $5 for day trading. If you want to skip our introduction to stock indicators and the broader market environment, then take a look at 5 Most Volatile Stocks Under $5 Fo... Full story
Yahoo Finance • last year
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update
WESTPORT, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial... Full story
Yahoo Finance • last year
Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
Updated data support the proof of concept of using an iNKT engager monotherapy (PORT-2) to induce immune response for patients with non-small cell lung cancer (NSCLC) and melanoma Strong academic interest in the design of the Adenosine 2A(... Full story
Yahoo Finance • last year
Portage Biotech Announces $6.0 Million Registered Direct Offering
WESTPORT, Conn., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that... Full story
Yahoo Finance • last year
Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference
WESTPORT, Conn., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that... Full story
Yahoo Finance • last year
Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors
WESTPORT, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today announced that it... Full story
Yahoo Finance • last year
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update
WESTPORT, Conn., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial... Full story
Yahoo Finance • last year
Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors
WESTPORT, Conn., June 26, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, announced today that i... Full story
Yahoo Finance • 2 years ago
Portage Biotech to Present at Oppenheimer’s 33rd Annual Healthcare Conference
WESTPORT, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that... Full story
Yahoo Finance • 2 years ago
Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer
Targeting Adenosine for Cancer: Challenging Past Assumptions with Next-Generation Small Molecule Inhibitors Thursday, March 9th @ 10:30 am ET WESTPORT, Conn., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a cli... Full story
Yahoo Finance • 2 years ago
Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit
WESTPORT, Conn., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that t... Full story
Yahoo Finance • 2 years ago
Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
WESTPORT, Conn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, today announced the presentation of upd... Full story
Yahoo Finance • 2 years ago
Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck
WESTPORT, Conn., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoidin... Full story
Yahoo Finance • 2 years ago
Portage Biotech to Present at Upcoming Investor Conferences
WESTPORT, Conn., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival, today announced that the Company’s man... Full story
Yahoo Finance • 2 years ago
Portage Biotech Announces Results for Fiscal Quarter Ended June 30, 2022
--Robust Pipeline Now Includes Five Clinical-Stage Small Molecule Immuno-Oncology Assets, Including Invariant Natural Killer T Cell (iNKT) Agonists and Adenosine Antagonists-- ---Cash Runway for New and Current Programs Potentially Extend... Full story
Yahoo Finance • 2 years ago
Portage Biotech Announces Leadership Updates
CEO Dr. Ian Walters to take on additional responsibility as Chairman of the Board Justin Fairchild, MPH, an expert in clinical immunotherapy, appointed Vice President of Development WESTPORT, Conn., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Po... Full story
Yahoo Finance • 2 years ago
UPDATE -- Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022
--Company Continues to Execute on Core Business Model While Enhancing Value Proposition and Pipeline with Recent Transactions-- --Robust Pipeline Now Includes Four Fully Owned, Clinical-Stage Assets-- --Cash Runway for New and Current Pr... Full story
Yahoo Finance • 2 years ago
Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022
--Company Continues to Execute on Core Business Model While Enhancing Value Proposition and Pipeline with Recent Transactions-- --Robust Pipeline Now Includes Four Fully Owned, Clinical-Stage Assets-- --Cash Runway for New and Current Pr... Full story
